Romosozumab May Not Increase Cardiovascular Risk After All ...Middle East

Medscape - News
Alarm bells went off at the FDA because during year 1 of the ARCH trial, the incidence of adjudicated major adverse cardiovascular events was 2.5% in the romosozumab arm, compared with 1.9% with alendronate. Medscape Medical News

Read More Details
Finally We wish PressBee provided you with enough information of ( Romosozumab May Not Increase Cardiovascular Risk After All )

Apple Storegoogle play

Also on site :



Latest News